Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism

Osteoporosis International

Volumn 21, Issue 9, 2010, Pages 1591-1597

  Vestergaard, P ^a   Schwartz, K ^b   Pinholt, E M ^b   Rejnmark, L ^a   Mosekilde, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bisphosphonate; Deep venous thromboembolism; Raloxifene; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DENMARK; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; PULMONARY EMBOLISM; RALOXIFENE; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 77956456133     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1091-y     Document Type: Article

References (19)

1. Delmas P, Ensrud K, Adachi J, Harper K, Sarkar S, Gennari C, Reginster J, Pols H, Recker R, Harris S, Wu W, Genant H, Black D, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: fouryear results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
2. Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H, Christiansen C, Delmas P, Zanchetta J, Stakkestad J, Gler C, Krueger K, Cohen F, Eckert S, Ensrud K, Avioli L, Lips P, Cummings S (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
3. Luíkin E, Whitaker M, Nickelsen T, Argueta R, Caplan R, Knickerbocker R, Riggs B (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747-1754
4. Seeman E, Crans G, Diez-Perez A, Pinette K, Delmas P (2006) Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 17:313-316
5. Siris E, Harris S, Eastell R, Zanchetta J, Goemaere S, Diez-Perez A, Stock J, Song J, Qu Y, Kulkarni P, Siddhanti S, Wong M, Cummings S (2005) Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Res 20:1514-1524
6. Barrett-Connor E, Mosca L, Collins P, Geiger M, Grady D, Kornitzer M, McNabb M, Wenger N (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137 (Pubitemid 44050394)
7. Adomaityte J, Farooq M, Qayyum R (2008) Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 99:338-342
8. O'Donnell S, Cranney A, Wells G, Adachi J, Reginster J (2006) Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 4: CD005326
9. Grosso A, Douglas I, Hingorani A, MacAllister R, Smeeth L (2008) Post-marketing assessment of the safety of strontium ranelate: a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 66:689-694
10. Riddell AJ (1996) Disseminated intravascular coagulation in metastatic prostate cancer. J Nucl Med 37:401
11. Leong C, McKenzie MR, Coupland DB, Gascoyne RD (1994) Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium-89 therapy. J Nucl Med 35:1662-1664
12. Andersen T, Madsen M, Jørgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263-268
13. Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality. Ugeskr Laeger 157:3741-3745
14. Coronary Drug Project Research Group (1980) Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. NEJM 303:1038-1041
15. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, Norton L, Nickelsen T, Bjarnason N, Morrow M, Lippman M, Black D, Glusman J, Costa A, Jordan V (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197
16. Vestergaard P, Mosekilde L (2003) Fracture risk associated with smoking-a meta-analysis. J Intern Med 254:572-583 (Pubitemid 37521854)
17. Beral V, Banks E, Reeves G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360:942-944
18. Vestergaard P, Rejnmark L, Mosekilde L (2008) Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer. Calcif Tissue Int 82:334-340
19. Alibhai S, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201-215